Effect of a Metalloantibiotic Produced by Pseudomonas aeruginosa on Klebsiella pneumoniae Carbapenemase (KPC)-producing K. pneumoniae
Multidrug-resistant organisms (MDRO) are a great problem in hospitals, where thousands of people are infected daily, with the occurrence of high mortality rates, especially in infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-producing Kpn). The challenge is to find new compounds that can control KPC producing-Kpn infections. The aim of this study was to evaluate the antibiotic activity of the F3d fraction produced by the Pseudomonas aeruginosa LV strain against clinical isolates of KPC-producing Kpn. The results showed that the minimum inhibitory concentration of F3d (62.5 µg mL(-1)), containing an organic metallic compound, killed planktonic cells of KPC-producing Kpn strains after 30 min of incubation. At the same concentration, this fraction also showed an inhibitory effect against biofilm of these bacteria after 24 h of incubation. Treatment with the F3d fraction caused pronounced morphological alterations in both planktonic and biofilm cells of the bacteria. The inhibitory effect of the F3d fraction seems to be more selective for the bacteria than the host cells, indicating its potential in the development of new drugs for the treatment of infections caused by KPC-producing Kpn and other MDRO.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2016 |
---|---|
Erschienen: |
2016 |
Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
---|---|
Enthalten in: |
Current pharmaceutical biotechnology - 17(2016), 4 vom: 19., Seite 389-97 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Kerbauy, Gilselena [VerfasserIn] |
---|
Themen: |
Anti-Bacterial Agents |
---|
Anmerkungen: |
Date Completed 11.08.2016 Date Revised 18.09.2019 published: Print Citation Status MEDLINE |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
NLM257617582 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM257617582 | ||
003 | DE-627 | ||
005 | 20231224183222.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231224s2016 xx |||||o 00| ||eng c | ||
028 | 5 | 2 | |a pubmed24n0858.xml |
035 | |a (DE-627)NLM257617582 | ||
035 | |a (NLM)26891742 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Kerbauy, Gilselena |e verfasserin |4 aut | |
245 | 1 | 0 | |a Effect of a Metalloantibiotic Produced by Pseudomonas aeruginosa on Klebsiella pneumoniae Carbapenemase (KPC)-producing K. pneumoniae |
264 | 1 | |c 2016 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 11.08.2016 | ||
500 | |a Date Revised 18.09.2019 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Multidrug-resistant organisms (MDRO) are a great problem in hospitals, where thousands of people are infected daily, with the occurrence of high mortality rates, especially in infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-producing Kpn). The challenge is to find new compounds that can control KPC producing-Kpn infections. The aim of this study was to evaluate the antibiotic activity of the F3d fraction produced by the Pseudomonas aeruginosa LV strain against clinical isolates of KPC-producing Kpn. The results showed that the minimum inhibitory concentration of F3d (62.5 µg mL(-1)), containing an organic metallic compound, killed planktonic cells of KPC-producing Kpn strains after 30 min of incubation. At the same concentration, this fraction also showed an inhibitory effect against biofilm of these bacteria after 24 h of incubation. Treatment with the F3d fraction caused pronounced morphological alterations in both planktonic and biofilm cells of the bacteria. The inhibitory effect of the F3d fraction seems to be more selective for the bacteria than the host cells, indicating its potential in the development of new drugs for the treatment of infections caused by KPC-producing Kpn and other MDRO | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
650 | 7 | |a Bacterial Proteins |2 NLM | |
650 | 7 | |a beta-Lactamases |2 NLM | |
650 | 7 | |a EC 3.5.2.6 |2 NLM | |
650 | 7 | |a carbapenemase |2 NLM | |
650 | 7 | |a EC 3.5.2.6 |2 NLM | |
700 | 1 | |a Vivan, Ana C P |e verfasserin |4 aut | |
700 | 1 | |a Simões, Glenda C |e verfasserin |4 aut | |
700 | 1 | |a Simionato, Ane S |e verfasserin |4 aut | |
700 | 1 | |a Pelisson, Marsileni |e verfasserin |4 aut | |
700 | 1 | |a Vespero, Eliana C |e verfasserin |4 aut | |
700 | 1 | |a Costa, Silvia F |e verfasserin |4 aut | |
700 | 1 | |a Andrade, Celia G T de J |e verfasserin |4 aut | |
700 | 1 | |a Barbieri, Daiane M |e verfasserin |4 aut | |
700 | 1 | |a Mello, João C P |e verfasserin |4 aut | |
700 | 1 | |a Morey, Alexandre T |e verfasserin |4 aut | |
700 | 1 | |a Yamauchi, Lucy M |e verfasserin |4 aut | |
700 | 1 | |a Yamada-Ogatta, Sueli F |e verfasserin |4 aut | |
700 | 1 | |a de Oliveira, Admilton G |e verfasserin |4 aut | |
700 | 1 | |a Andrade, Galdino |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Current pharmaceutical biotechnology |d 2000 |g 17(2016), 4 vom: 19., Seite 389-97 |w (DE-627)NLM11369072X |x 1873-4316 |7 nnns |
773 | 1 | 8 | |g volume:17 |g year:2016 |g number:4 |g day:19 |g pages:389-97 |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 17 |j 2016 |e 4 |b 19 |h 389-97 |